Vildagliptin is indicated in the treatment of type 2 diabetes mellitus in adults:
As monotherapy
- in patients inadequately controlled by diet and exercise alone and for whom metformin is inappropriate due
to contraindications or intolerance.
As dual oral therapy in combination with
- metformin, in patients with insufficient glycaemic control despite maximal tolerated dose of monotherapy with
metformin,
- a sulphonylurea, in patients with insufficient glycaemic control despite maximal tolerated dose of a
sulphonylurea and for whom metformin is inappropriate due to contraindications or intolerance,
- a thiazolidinedione, in patients with insufficient glycaemic control and for whom the use of a thiazolidinedione
is appropriate.
As triple oral therapy in combination with
- a sulphonylurea and metformin when diet and exercise plus dual therapy with these medicinal products do
not provide adequate glycaemic control.
Vildagliptin is also indicated for use in combination with insulin (with or without metformin) when diet and
exercise plus a stable dose of insulin do not provide adequate glycaemic control.

Posology
Adults
When used as monotherapy, in combination with metformin, in combination with thiazolidinedione, in
combination with metformin and a sulphonylurea, or in combination with insulin (with or without metformin), the
recommended daily dose of vildagliptin is 100 mg, administered as one dose of 50 mg in the morning and one
dose of 50 mg in the evening.
2
When used in dual combination with a sulphonylurea, the recommended dose of vildagliptin is 50 mg once daily administered in the morning. In this patient population, vildagliptin 100 mg daily was no more effective than vildagliptin 50 mg once daily.
When used in combination with a sulphonylurea, a lower dose of the sulphonylurea may be considered to reduce the risk of hypoglycaemia.
Doses higher than 100 mg are not recommended.
If a dose of Diaglipt is missed, it should be taken as soon as the patient remembers. A double dose should not be taken on the same day.
The safety and efficacy of vildagliptin as triple oral therapy in combination with metformin and a thiazolidinedione have not been established.
Additional information on special populations
Elderly (≥ 65 years)
No dose adjustments are necessary in elderly patients (see also sections 5.1 and 5.2).

Renal impairment
No dose adjustment is required in patients with mild renal impairment (creatinine clearance ≥ 50 ml/min). In patients with moderate or severe renal impairment or with end-stage renal disease (ESRD), the recommended dose of Diaglipt is 50 mg once daily (see also sections 4.4, 5.1 and 5.2).
Hepatic impairment
Diaglipt should not be used in patients with hepatic impairment, including patients with pre-treatment alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 3x the upper limit of normal (ULN) (see also sections 4.4 and 5.2).
Paediatric population
Diaglipt is not recommended for use in children and adolescents (< 18 years). The safety and efficacy of Diaglipt in children and adolescents (< 18 years) have not been established. No data are available (see also section 5.1).
Method of administration
Oral use
Diaglipt can be administered with or without a meal (see also section 5.2).

General
Diaglipt is not a substitute for insulin in insulin-requiring patients. Diaglipt should not be used in patients with type 1 diabetes or for the treatment of diabetic ketoacidosis.
Renal impairment
There is limited experience in patients with ESRD on haemodialysis. Therefore, Diaglipt should be used with caution in these patients (see also sections 4.2, 5.1 and 5.2).
3
Hepatic impairment
Diaglipt should not be used in patients with hepatic impairment, including patients with pre-treatment ALT or AST > 3x ULN (see also sections 4.2 and 5.2).
Liver enzyme monitoring
Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function test results returned to normal after discontinuation of treatment. Liver function tests should be performed prior to the initiation of treatment with Diaglipt in order to know the patient's baseline value. Liver function should be monitored during treatment with Diaglipt at three-month intervals during the first year and periodically thereafter. Patients who develop increased transaminase levels should be monitored with a second liver function evaluation to confirm the finding and be followed thereafter with frequent liver function tests until the abnormality(ies) return(s) to normal. Should an increase in AST or ALT of 3x ULN or greater persist, withdrawal of Diaglipt therapy is recommended.

Patients who develop jaundice or other signs suggestive of liver dysfunction should discontinue Diaglipt. Following withdrawal of treatment with Diaglipt and LFT normalisation, treatment with Diaglipt should not be
reinitiated. Cardiac failure
A clinical trial of vildagliptin in patients with New York Heart Association (NYHA) functional class I-III showed that treatment with vildagliptin was not associated with a change in left-ventricular function or worsening of pre- existing congestive heart failure (CHF) versus placebo. Clinical experience in patients with NYHA functional class III treated with vildagliptin is still limited and results are inconclusive (see section 5.1).
There is no experience of vildagliptin use in clinical trials in patients with NYHA functional class IV and therefore use is not recommended in these patients.
Skin disorders
Skin lesions, including blistering and ulceration have been reported in extremities of monkeys in non-clinical toxicology studies (see section 5.3). Although skin lesions were not observed at an increased incidence in clinical trials, there was limited experience in patients with diabetic skin complications. Furthermore, there have been post-marketing reports of bullous and exfoliative skin lesions. Therefore, in keeping with routine care of the diabetic patient, monitoring for skin disorders, such as blistering or ulceration, is recommended.
Acute pancreatitis
Use of vildagliptin has been associated with a risk of developing acute pancreatitis. Patients should be informed of the characteristic symptom of acute pancreatitis.
If pancreatitis is suspected, vildagliptin should be discontinued; if acute pancreatitis is confirmed, vildagliptin should not be restarted. Caution should be exercised in patients with a history of acute pancreatitis.
Hypoglycaemia
Sulphonylureas are known to cause hypoglycaemia. Patients receiving vildagliptin in combination with a sulphonylurea may be at risk for hypoglycaemia. Therefore, a lower dose of sulphonylurea may be considered to reduce the risk of hypoglycaemia.

Excipients
This medicine contains lactose. Patients with rare hereditary problems of galactose intolerance, total lactase deficiency or glucose-galactose malabsorption should not take this medicine.

Vildagliptin has a low potential for interactions with co -administered medicinal products. Since vildagliptin is not a cytochrome P (CYP) 450 enzyme substrate and does not inhibit or induce CYP 450 enzymes, it is not likely to interact with active substanc es that are substrates, inhibitors or inducers of these enzymes.
4
Combination with pioglitazone, metformin and glyburide
Results from studies conducted with these oral antidiabetics have shown no clinically relevant pharmacokinetic interactions.
Digoxin (Pgp substrate), warfarin (CYP2C9 substrate)
Clinical studies performed with healthy subjects have shown no clinically relevant pharmacokinetic interactions. However, this has not been established in the target population.
Combination with amlodipine, ramipril, valsartan or simvastatin
Drug-drug interaction studies in healthy subjects were conducted with amlodipine, ramipril, valsartan and simvastatin. In these studies, no clinically relevant pharmacokinetic interactions were obser ved after co-administration with vildagliptin.
Combination with ACE -inhibitors
There may be an increased risk of angioedema in patients concomitantly taking ACE -inhibitors. (See section 4.8).

As with other oral antidiabetic medicinal products the hypogl ycaemic effect of vildagliptin may be reduced by certain active substances, including thiazides, corticosteroids, thyroid products and sympathomimetics.

Pregnancy
There are no adequate data from the use of vildagliptin in pregnant women. Studies in animals have shown reproductive toxicity at high doses (see section 5.3). The potential risk for humans is unknown. Due to lack of human data, Diaglipt should not be used during pregnancy.
Breast-feeding
It is unknown whether vildagliptin is excreted in human milk. Animal studies have shown excretion of vildagliptin in milk. Diaglipt should not be used during breast-feeding.
Fertility
No studies on the effect on human fertility have been conducted for Diaglipt (see section 5.3).

No studies on the effects on the ability to drive and use machines have been performed. Patients who experience dizziness as an adverse reaction should avoid driving vehicles or using machines.

Summary of the safety profile
Safety data were obtained from a total of 3,784 patients exposed to vildagliptin at a daily dose of 50 mg (once daily) or 100 mg (50 mg twice daily or 100 mg once daily) in controlled trials of at least 12 weeks duration. Of these patients, 2,264 patients received vildagliptin as monotherapy and 1,520 patients received vildagliptin in combination with another medicinal product. 2,682 patients were treated with vildagliptin 100 mg daily (either 50 mg twice daily or 100 mg once daily) and 1,102 patients were treated with vildagliptin 50 mg once daily.
The majority of adverse reactions in these trials were mild and transient, not requiring treatment discontinuations. No association was found between adverse reactions and age, ethnicity, duration of exposure or daily dose.
Rare cases of hepatic dysfunction (including hepatitis) have been reported. In these cases, the patients were generally asymptomatic without clinical sequelae and liver function returned to normal after discontinuation of treatment. In data from controlled monotherapy and add-on therapy trials of up to 24 weeks in duration, the incidence of ALT or AST elevations ≥ 3x ULN (classified as present on at least 2 consecutive measurements or at the final on-treatment visit) was 0.2%, 0.3% and 0.2% for vildagliptin 50 mg once daily, vildagliptin 50 mg
5
twice daily and all comparators, respectively. These elevations in transaminases were generally asymptomatic, non-progressive in nature and not associated with cholestasis or jaundice.
Rare cases of angioedema have been reported on vildagliptin at a similar rate to controls. A greater proportion of cases were reported when vildagliptin was administered in combination with an angiotensin converting enzyme inhibitor (ACE-Inhibitor). The majority of events were mild in severity and resolved with ongoing vildagliptin treatment.

Tabulated list of adverse reactions
Adverse reactions reported in patients who received Diaglipt in double-blind studies as monotherapy and add- on therapies are listed below for each indication by system organ class and absolute frequency. Frequencies are defined as very common (≥1/10), common (≥1/100 to <1/10), uncommon (≥1/1,000 to <1/100), rare (≥1/10,000 to <1/1,000), very rare (<1/10,000), not known (cannot be estimated from the available data). Within each frequency grouping, adverse reactions are presented in order of decreasing seriousness.
Combination with metformin
Table 1 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with metformin in double-blind studies (N=208)
Metabolism and nutrition disorders
Common
Hypoglycaemia
Nervous system disorders
Common
Tremor
Common
Headache
Common
Dizziness
Uncommon
Fatigue
Gastrointestinal disorders
Common
Nausea
Description of selected adverse reactions
In controlled clinical trials with the combination of vildagliptin 100 mg daily + metformin, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + metformin or the placebo + metformin treatment groups.
In clinical trials, the incidence of hypoglycaemia was common in patients receiving vildagliptin 100 mg daily in combination with metformin (1%) and uncommon in patients receiving placebo + metformin (0.4%). No severe hypoglycaemic events were reported in the vildagliptin arms.
In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was added to metformin (+0.2 kg and -1.0 kg for vildagliptin and placebo, respectively).
Clinical trials of up to more than 2 years' duration did not show any additional safety signals or unforeseen risks when vildagliptin was added on to metformin.

Combination with a sulphonylurea
Table 2 Adverse reactions reported in patients who received Diaglipt 50 mg in combination with a sulphonylurea in double-blind studies (N=170)
Infections and infestations
Very rare
Nasopharyngitis
Metabolism and nutrition disorders
Common
Hypoglycaemia
Nervous system disorders
Common
Tremor
Common
Headache
Common
Dizziness
Common
Asthenia
Gastrointestinal disorders
Uncommon
Constipation
Description of selected adverse reactions
6
In controlled clinical trials with the combination of vildagliptin 50 mg + a sulphonylurea, the overall incidence of withdrawals due to adverse reactions was 0.6% in the vildagliptin 50 mg + sulphonylurea vs 0% in the placebo
+ sulphonylurea treatment group.
In clinical trials, the incidence of hypoglycaemia when vildagliptin 50 mg once daily was added to glimepiride was 1.2% versus 0.6% for placebo + glimepiride. No severe hypoglycaemic events were reported in the vildagliptin arms.
In clinical trials, weight did not change from baseline when vildagliptin 50 mg daily was added to glimepiride (-
0.1 kg and -0.4 kg for vildagliptin and placebo, respectively).

Combination with a thiazolidinedione
Table 3 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with a thiazolidinedione in double-blind studies (N=158)
Metabolism and nutrition disorders
Common
Weight increase
Uncommon
Hypoglycaemia
Nervous system disorders
Uncommon
Headache
Uncommon
Asthenia
Vascular disorders
Common
Oedema peripheral
Description of selected adverse reactions
In controlled clinical trials with the combination of vildagliptin 100 mg daily+ a thiazolidinedione, no withdrawal due to adverse reactions was reported in either the vildagliptin 100 mg daily + thiazolidinedione or the placebo
+ thiazolidinedione treatment groups.
In clinical trials, the incidence of hypoglycaemia was uncommon in patients receiving vildagliptin + pioglitazone (0.6%) but common in patients receiving placebo + pioglitazone (1.9%). No severe hypoglycaemic events were reported in the vildagliptin arms.
In the pioglitazone add-on study, the absolute weight increases with placebo, Diaglipt 100 mg daily were 1.4 and 2.7 kg, respectively.
The incidence of peripheral oedema when vildagliptin 100 mg daily was added to a maximum dose of background pioglitazone (45 mg once daily) was 7.0%, compared to 2.5% for background pioglitazone alone.

Monotherapy
Table 4 Adverse reactions reported in patients who received Diaglipt 100 mg daily as monotherapy in double-blind studies (N=1,855)
Infections and infestations
Very rare
Upper respiratory tract infection
Very rare
Nasopharyngitis
Metabolism and nutrition disorders
Uncommon
Hypoglycaemia
Nervous system disorders
Common
Dizziness
Uncommon
Headache
Vascular disorders
Uncommon
Oedema peripheral
Gastrointestinal disorders
Uncommon
Constipation
Musculoskeletal and connective tissue disorders
Uncommon
Arthralgia
Description of selected adverse reactions
7
In addition, in controlled monotherapy trials with vildagliptin the overall incidence of withdrawals due to adverse reactions was no greater for patients treated with vildagliptin at doses of 100 mg daily (0.3%) than for placebo (0.6%) or comparators (0.5%).

In comparative controlled monotherapy studies, hypoglycaemia was uncommon, reported in 0.4% (7 of 1,855) of patients treated with vildagliptin 100 mg daily compared to 0.2% (2 of 1,082) of patients in the groups treated with an active comparator or placebo, with no serious or severe events reported.
In clinical trials, weight did not change from baseline when vildagliptin 100 mg daily was administered as monotherapy (-0.3 kg and -1.3 kg for vildagliptin and placebo, respectively).
Clinical trials of up to 2 years' duration did not show any additional safety signals or unforeseen risks with vildagliptin monotherapy.
Combination with metformin and a sulphonylurea
Table 5 Adverse reactions reported in patients who received Diaglipt 50 mg twice daily in combination with metformin and a sulphonylurea (N=157)
Metabolism and nutritional disorders
Common
Hypoglycaemia
Nervous system disorders
Common
Dizziness, tremor
Skin and subcutaneous tissue disorders
Common
Hyperhidrosis
General disorders and administration site conditions
Common
Asthenia
Description of selected adverse reactions
There were no withdrawals due to adverse reactions reported in the vildagliptin + metformin + glimepiride treatment group versus 0.6% in the placebo + metformin + glimepiride treatment group.
The incidence of hypoglycaemia was common in both treatment groups (5.1% for the vildagliptin + metformin
+ glimepiride group versus 1.9% for the placebo + metformin + glimepiride group). One severe hypoglycaemic event was reported in the vildagliptin group.
At the end of the study, effect on mean body weight was neutral (+0.6 kg in the vildagliptin group and -0.1 kg in the placebo group).

Combination with insulin
Table 6 Adverse reactions reported in patients who received Diaglipt 100 mg daily in combination with insulin (with or without metformin) in double-blind studies (N=371)
Metabolism and nutrition disorders
Common
Decreased blood glucose
Nervous system disorders
Common
Headache, chills
Gastrointestinal disorders
Common
Nausea, gastro-oesophageal reflux disease
Uncommon
Diarrhoea, flatulence
Description of selected adverse reactions
In controlled clinical trials using vildagliptin 50 mg twice daily in combination with insulin, with or without concomitant metformin, the overall incidence of withdrawals due to adverse reactions was 0.3% in the vildagliptin treatment group and there were no withdrawals in the placebo group.
The incidence of hypoglycaemia was similar in both treatment groups (14.0% in the vildagliptin group vs 16.4% in the placebo group). Two patients reported severe hypoglycaemic events in the vildagliptin group, and 6 patients in the placebo group.
At the end of the study, effect on mean body weight was neutral (+0.6 kg change from baseline in the vildagliptin group and no weight change in the placebo group).

Post-marketing experience
Table 7 Post-marketing adverse reactions
Gastrointestinal disorders
Not known Pancreatitis
Hepatobiliary disorders
Not known Hepatitis (reversible upon discontinuation of the medicinal product)
Abnormal liver function tests (reversible upon discontinuation of the medicinal product)
Musculoskeletal and connective tissue disorders
Not known Myalgia
Skin and subcutaneous tissue disorders
Not known Urticaria
Exfoliative and bullous skin lesions, including bullous pemphigoid
To Report any side effects:
Saudi Arabia:
The National Pharmacovigilance Centre (NPC)
o SFDA call center: 19999
o E-mail: npc.drug@sfda.gov.sa
o Website: https://ade.sfda.gov.sa
Other GCC States:
- Please contact the relevant competent authority

Information regarding overdose with vildagliptin is limited.
Symptoms
Information on the likely symptoms of overdose was taken from a rising dose tolerability study in healthy
subjects given Diaglipt for 10 days. At 400 mg, there were three cases of muscle pain, and individual cases of
mild and transient paraesthesia, fever, oedema and a transient increase in lipase levels. At 600 mg, one subject
experienced oedema of the feet and hands, and increases in creatine phosphokinase (CPK), aspartate
aminotransferase (AST), C-reactive protein (CRP) and myoglobin levels. Three other subjects experienced
oedema of the feet, with paraesthesia in two cases. All symptoms and laboratory abnormalities resolved
without treatment after discontinuation of the study medicinal product.
Management
In the event of an overdose, supportive management is recommended. Vildagliptin cannot be removed by
haemodialysis. However, the major hydrolysis metabolite (LAY 151) can be removed by haemodialysis.

Pharmacotherapeutic group: Drugs used in diabetes, dipeptidyl peptidase 4 (DPP-4) inhibitors, ATC code:
A10BH02
Vildagliptin, a member of the islet enhancer class, is a potent and selective DPP-4 inhibitor.
Mechanism of action
The administration of vildagliptin results in a rapid and complete inhibition of DPP-4 activity, resulting in
increased fasting and postprandial endogenous levels of the incretin hormones GLP-1 (glucagon-like peptide
1) and GIP (glucose-dependent insulinotropic polypeptide).
9
Pharmacodynamic effects
By increasing the endogenous levels of these incretin hormones, vildagliptin enhances the sensitivity of beta cells to glucose, resulting in improved glucose-dependent insulin secretion. Treatment with vildagliptin 50-100 mg daily in patients with type 2 diabetes significantly improved markers of beta cell function including HOMA- β (Homeostasis Model Assessment–β), proinsulin to insulin ratio and measures of beta cell responsiveness from the frequently-sampled meal tolerance test. In non-diabetic (normal glycaemic) individuals, vildagliptin does not stimulate insulin secretion or reduce glucose levels.
By increasing endogenous GLP-1 levels, vildagliptin also enhances the sensitivity of alpha cells to glucose, resulting in more glucose-appropriate glucagon secretion.
The enhanced increase in the insulin/glucagon ratio during hyperglycaemia due to increased incretin hormone levels results in a decrease in fasting and postprandial hepatic glucose production, leading to reduced glycaemia.
The known effect of increased GLP-1 levels delaying gastric emptying is not observed with vildagliptin treatment.

Clinical efficacy and safety
More than 15,000 patients with type 2 diabetes participated in double-blind placebo- or active-controlled clinical trials of up to more than 2 years' treatment duration. In these studies, vildagliptin was administered to more than 9,000 patients at daily doses of 50 mg once daily, 50 mg twice daily or 100 mg once daily. More than 5,000 male and more than 4,000 female patients received vildagliptin 50 mg once daily or 100 mg daily. More than 1,900 patients receiving vildagliptin 50 mg once daily or 100 mg daily were ≥ 65 years. In these trials, vildagliptin was administered as monotherapy in drug-naïve patients with type 2 diabetes or in combination in patients not adequately controlled by other antidiabetic medicinal products.
Overall, vildagliptin improved glycaemic control when given as monotherapy or when used in combination with metformin, a sulphonylurea, and a thiazolidinedione, as measured by clinically relevant reductions in HbA1c from baseline at study endpoint (see Table 8).
In clinical trials, the magnitude of HbA1c reductions with vildagliptin was greater in patients with higher baseline HbA1c.
In a 52-week double-blind controlled trial, vildagliptin (50 mg twice daily) reduced baseline HbA1c by -1% compared to -1.6% for metformin (titrated to 2 g/day) statistical non-inferiority was not achieved. Patients treated with vildagliptin reported significantly lower incidences of gastrointestinal adverse reactions versus those treated with metformin.
In a 24-week double-blind controlled trial, vildagliptin (50 mg twice daily) was compared to rosiglitazone (8 mg once daily). Mean reductions were -1.20% with vildagliptin and -1.48% with rosiglitazone in patients with mean baseline HbA1c of 8.7%. Patients receiving rosiglitazone experienced a mean increase in weight (+1.6 kg) while those receiving vildagliptin experienced no weight gain (-0.3 kg). The incidence of peripheral oedema was lower in the vildagliptin group than in the rosiglitazone group (2.1% vs. 4.1% respectively).
In a clinical trial of 2 years' duration, vildagliptin (50 mg twice daily) was compared to gliclazide (up to 320 mg/day). After two years, mean reduction in HbA1c was -0.5% for vildagliptin and -0.6% for gliclazide, from a mean baseline HBA1c of 8.6%. Statistical non-inferiority was not achieved. Vildagliptin was associated with fewer hypoglycaemic events (0.7%) than gliclazide (1.7%).
In a 24-week trial, vildagliptin (50 mg twice daily) was compared to pioglitazone (30 mg once daily) in patients inadequately controlled with metformin (mean daily dose: 2020 mg). Mean reductions from baseline HbA1c of 8.4% were -0.9% with vildagliptin added to metformin and -1.0% with pioglitazone added to metformin. A mean weight gain of +1.9 kg was observed in patients receiving pioglitazone added to metformin compared to +0.3 kg in those receiving vildagliptin added to metformin.

In a clinical trial of 2 years' duration, vildagliptin (50 mg twice daily) was compared to glimepiride (up to 6 mg/day – mean dose at 2 years: 4.6 mg) in patients treated with metformin (mean daily dose: 1894 mg). After 1 year mean reductions in HbA1c were -0.4% with vildagliptin added to metformin and -0.5% with glimepiride added to metformin, from a mean baseline HbA1c of 7.3%. Body weight change with vildagliptin was -0.2 kg vs
+1.6 kg with glimepiride. The incidence of hypoglycaemia was significantly lower in the vildagliptin group (1.7%) than in the glimepiride group (16.2%). At study endpoint (2 years), the HbA1c was similar to baseline values in
both treatment groups and the body weight changes and hypoglycaemia differences were maintained.
In a 52-week trial, vildagliptin (50 mg twice daily) was compared to gliclazide (mean daily dose: 229.5 mg) in patients inadequately controlled with metformin (metformin dose at baseline 1928 mg/day). After 1 year, mean reductions in HbA1c were -0.81% with vildagliptin added to metformin (mean baseline HbA1c 8.4%) and -0.85% with gliclazide added to metformin (mean baseline HbA1c 8.5%); statistical non-inferiority was achieved (95%
10
CI -0.11 – 0.20). Body weight change with vildagliptin was +0.1 kg compared to a weight gain of +1.4 kg with gliclazide.
In a 24-week trial the efficacy of the fixed dose combination of vildagliptin and metformin (gradually titrated to a dose of 50 mg/500 mg twice daily or 50 mg/1000 mg twice daily) as initial therapy in drug-naïve patients was evaluated. Vildagliptin/metformin 50 mg/1000 mg twice daily reduced HbA1c by -1.82%, vildagliptin/metformin 50 mg/500 mg twice daily by -1.61%, metformin 1000 mg twice daily by -1.36% and vildagliptin 50 mg twice daily by -1.09% from a mean baseline HbA1c of 8.6%. The decrease in HbA1c observed in patients with a baseline ≥10.0% was greater.

A 24-week, multi-centre, randomised, double-blind, placebo-controlled trial was conducted to evaluate the treatment effect of vildagliptin 50 mg once daily compared to placebo in 515 patients with type 2 diabetes and moderate renal impairment (N=294) or severe renal impairment (N=221). 68.8% and 80.5% of the patients with moderate and severe renal impairment respectively were treated with insulin (mean daily dose of 56 units and 51.6 units respectively) at baseline. In patients with moderate renal impairment vildagliptin significantly decreased HbA1c compared with placebo (difference of -0.53%) from a mean baseline of 7.9%. In patients with severe renal impairment, vildagliptin significantly decreased HbA1c compared with placebo (difference of - 0.56%) from a mean baseline of 7.7%.
A 24-week randomised, double-blind, placebo-controlled trial was conducted in 318 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with metformin (≥1500 mg daily) and glimepiride (≥4 mg daily). Vildagliptin in combination with metformin and glimepiride significantly decreased HbA1c compared with placebo.The placebo-adjusted mean reduction from a mean baseline HbA1c of 8.8% was
-0.76%.
A 24-week randomised, double-blind, placebo-controlled trial was conducted in 449 patients to evaluate the efficacy and safety of vildagliptin (50 mg twice daily) in combination with a stable dose of basal or premixed insulin (mean daily dose 41 units), with concomitant use of metformin (N=276) or without concomitant metformin (N=173). Vildagliptin in combination with insulin significantly decreased HbA1c compared with placebo. In the overall population, the placebo-adjusted mean reduction from a mean baseline HbA1c 8.8% was
-0.72%. In the subgroups treated with insulin with or without concomitant metformin the placebo-adjusted mean reduction in HbA1c was -0.63% and -0.84%, respectively. The incidence of hypoglycaemia in the overall population was 8.4% and 7.2% in the vildagliptin and placebo groups, respectively. Patients receiving vildagliptin experienced no weight gain (+0.2 kg) while those receiving placebo experienced weight reduction (-0.7 kg).
In another 24-week study in patients with more advanced type 2 diabetes not adequately controlled on insulin (short and longer acting, average insulin dose 80 IU/day), the mean reduction in HbA1c when vildagliptin (50 mg twice daily) was added to insulin was statistically significantly greater than with placebo plus insulin (0.5% vs. 0.2%). The incidence of hypoglycaemia was lower in the vildagliptin group than in the placebo group (22.9% vs. 29.6%).

A 52-week multi-centre, randomised, double-blind trial was conducted in patients with type 2 diabetes and congestive heart failure (NYHA functional class I-III) to evaluate the effect of vildagliptin 50 mg twice daily (N=128) compared to placebo (N=126) on left-ventricular ejection fraction (LVEF). Vildagliptin was not associated with a change in left-ventricular function or worsening of pre-existing CHF. Adjudicated cardiovascular events were balanced overall. There were more cardiac events in vildagliptin treated patients with NYHA class III heart failure compared to placebo. However, there were imbalances in baseline cardiovascular risk favouring placebo and the number of events was low, precluding firm conclusions. Vildagliptin significantly decreased HbA1c compared with placebo (difference of 0.6%) from a mean baseline of 7.8% at week 16. In the subgroup with NYHA class III, the decrease in HbA1c compared to placebo was lower (difference 0.3%) but this conclusion is limited by the small number of patients (n=44). The incidence of hypoglycaemia in the overall population was 4.7% and 5.6% in the vildagliptin and placebo groups, respectively.
Cardiovascular risk
A meta-analysis of independently and prospectively adjudicated cardiovascular events from 37 phase III and IV monotherapy and combination therapy clinical studies of up to more than 2 years duration (mean exposure 50 weeks for vildagliptin and 49 weeks for comparators) was performed and showed that vildagliptin treatment was not associated with an increase in cardiovascular risk versus comparators. The composite endpoint of adjudicated major adverse cardiovascular events (MACE) including acute myocardial infarction, stroke or cardiovascular death was similar for vildagliptin versus combined active and placebo comparators [Mantel– Haenszel risk ratio (M-H RR) 0.82 (95% CI 0.61-1.11)]. A MACE occurred in 83 out of 9,599 (0.86%) vildagliptin-treated patients and in 85 out of 7,102 (1.20%) comparator-treated patients. Assessment of each individual MACE component showed no increased risk (similar M-H RR). Confirmed heart failure (HF) events defined as HF requiring hospitalisation or new onset of HF were reported in 41 (0.43%) vildagliptin-treated patients and 32 (0.45%) comparator-treated patients with M-H RR 1.08 (95% CI 0.68-1.70).

Table 8 Key efficacy results of vildagliptin in placebo-controlled monotherapy trials and in add-on combination therapy trials (primary efficacy ITT population)
Monotherapy placebo-controlled studies
Mean baseline HbA1c (%)
Mean change from baseline in HbA1c (%) at week 24
Placebo-corrected mean change in HbA1c (%) at week 24 (95%CI)
Study 2301: Vildagliptin 50 mg twice daily (N=90)
8.6
-0.8
-0.5* (-0.8, -0.1)
Study 2384: Vildagliptin 50 mg twice daily (N=79)
8.4
-0.7
-0.7* (-1.1, -0.4)
*p< 0.05 for comparison versus placebo
Add-on / Combination studies
Vildagliptin 50 mg twice daily + metformin (N=143)
8.4
-0.9
-1.1* (-1.4, -0.8)
Vildagliptin 50 mg daily + glimepiride (N=132)
8.5
-0.6
-0.6* (-0.9, -0.4)
Vildagliptin 50 mg twice daily + pioglitazone (N=136)
8.7
-1.0
-0.7* (-0.9, -0.4)
Vildagliptin 50 mg twice daily + metformin + glimepiride (N=152)
8.8
-1.0
-0.8* (-1.0, -0.5)
*p< 0.05 for comparison versus placebo +comparator
Paediatric population
The European Medicines Agency has waived the obligation to submit the results of studies with vildagliptin in all subsets of the paediatric population with type 2 diabetes mellitus (see section 4.2 for information on paediatric use).

Absorption
Following oral administration in the fasting state, vildagliptin is rapidly absorbed, with peak plasma concentrations observed at 1.7 hours. Food slightly delays the time to peak plasma concentration to 2.5 hours, but does not alter the overall exposure (AUC). Administration of vildagliptin with food resulted in a decreased Cmax (19%). However, the magnitude of change is not clinically significant, so that Diaglipt can be given with or without food. The absolute bioavailability is 85%.
Distribution
The plasma protein binding of vildagliptin is low (9.3%) and vildagliptin distributes equally between plasma and red blood cells. The mean volume of distribution of vildagliptin at steady-state after intravenous administration (Vss) is 71 litres, suggesting extravascular distribution.
Biotransformation
Metabolism is the major elimination pathway for vildagliptin in humans, accounting for 69% of the dose. The major metabolite (LAY 151) is pharmacologically inactive and is the hydrolysis product of the cyano moiety, accounting for 57% of the dose, followed by the glucuronide (BQS867) and the amide hydrolysis products (4% of dose). In vitro data in human kidney microsomes suggest that the kidney may be one of the major organs contributing to the hydrolysis of vildagliptin to its major inactive metabolite, LAY151. DPP-4 contributes partially to the hydrolysis of vildagliptin based on an in vivo study using DPP-4 deficient rats. Vildagliptin is not metabolised by CYP 450 enzymes to any quantifiable extent. Accordingly, the metabolic clearance of vildagliptin is not anticipated to be affected by co-medications that are CYP 450 inhibitors and/or inducers. In vitro studies demonstrated that vildagliptin does not inhibit/induce CYP 450 enzymes. Therefore, vildagliptin is not likely to affect metabolic clearance of co-medications metabolised by CYP 1A2, CYP 2C8, CYP 2C9, CYP 2C19, CYP 2D6, CYP 2E1 or CYP 3A4/5.

Elimination
Following oral administration of [14C] vildagliptin, approximately 85% of the dose was excreted into the urine
and 15% of the dose is recovered in the faeces. Renal excretion of the unchanged vildagliptin accounted for
23% of the dose after oral administration. After intravenous administration to healthy subjects, the total plasma
and renal clearances of vildagliptin are 41 and 13 l/h, respectively. The mean elimination half-life after
intravenous administration is approximately 2 hours. The elimination half-life after oral administration is
approximately 3 hours.
Linearity/non-linearity
The Cmax for vildagliptin and the area under the plasma concentrations versus time curves (AUC) increased in
an approximately dose proportional manner over the therapeutic dose range.
Characteristics in specific groups of patients
Gender
No clinically relevant differences in the pharmacokinetics of vildagliptin were observed between male and
female healthy subjects within a wide range of age and body mass index (BMI). DPP-4 inhibition by vildagliptin
is not affected by gender.
Elderly
In healthy elderly subjects (≥ 70 years), the overall exposure of vildagliptin (100 mg once daily) was increased
by 32%, with an 18% increase in peak plasma concentration as compared to young healthy subjects (18-40
years). These changes are, however, not considered to be clinically relevant. DPP-4 inhibition by vildagliptin
is not affected by age.
Hepatic impairment
The effect of impaired hepatic function on the pharmacokinetics of vildagliptin was studied in patients with mild,
moderate and severe hepatic impairment based on the Child-Pugh scores (ranging from 6 for mild to 12 for
severe) in comparison with healthy subjects. The exposure to vildagliptin after a single dose in patients with
mild and moderate hepatic impairment was decreased (20% and 8%, respectively), while the exposure to
vildagliptin for patients with severe impairment was increased by 22%. The maximum change (increase or
decrease) in the exposure to vildagliptin is ~30%, which is not considered to be clinically relevant. There was
no correlation between the severity of the hepatic disease and changes in the exposure to vildagliptin.

Renal impairment
A multiple-dose, open-label trial was conducted to evaluate the pharmacokinetics of the lower therapeutic dose
of vildagliptin (50 mg once daily) in patients with varying degrees of chronic renal impairment defined by
creatinine clearance (mild: 50 to <80 ml/min, moderate: 30 to <50 ml/min and severe: <30 ml/min) compared
to normal healthy control subjects.
Vildagliptin AUC increased on average 1.4, 1.7 and 2-fold in patients with mild, moderate and severe renal
impairment, respectively, compared to normal healthy subjects. AUC of the metabolites LAY151 and BQS867
increased on average about 1.5, 3 and 7-fold in patients with mild, moderate and severe renal impairment,
respectively. Limited data from patients with end stage renal disease (ESRD) indicate that vildagliptin exposure
is similar to that in patients with severe renal impairment. LAY151 concentrations were approximately 2-3-fold
higher than in patients with severe renal impairment.
Vildagliptin was removed by haemodialysis to a limited extent (3% over a 3-4 hour haemodialysis session
starting 4 hours post dose).
Ethnic group
Limited data suggest that race does not have any major influence on vildagliptin pharmacokinetics.
 

Intra-cardiac impulse conduction delays were observed in dogs with a no-effect dose of 15 mg/kg (7-fold human
exposure based on Cmax).
Accumulation of foamy alveolar macrophages in the lung was observed in rats and mice. The no-effect dose
in rats was 25 mg/kg (5-fold human exposure based on AUC) and in mice 750 mg/kg (142-fold human
exposure).
Gastrointestinal symptoms, particularly soft faeces, mucoid faeces, diarrhoea and, at higher doses, faecal
blood were observed in dogs. A no-effect level was not established.
Vildagliptin was not mutagenic in conventional in vitro and in vivo tests for genotoxicity.

A fertility and early embryonic development study in rats revealed no evidence of impaired fertility, reproductive
performance or early embryonic development due to vildagliptin. Embryo-foetal toxicity was evaluated in rats
and rabbits. An increased incidence of wavy ribs was observed in rats in association with reduced maternal
body weight parameters, with a no-effect dose of 75 mg/kg (10-fold human exposure). In rabbits, decreased
foetal weight and skeletal variations indicative of developmental delays were noted only in the presence of
severe maternal toxicity, with a no-effect dose of 50 mg/kg (9-fold human exposure). A pre- and postnatal
development study was performed in rats. Findings were only observed in association with maternal toxicity at
≥ 150 mg/kg and included a transient decrease in body weight and reduced motor activity in the F1 generation.
A two-year carcinogenicity study was conducted in rats at oral doses up to 900 mg/kg (approximately 200
times human exposure at the maximum recommended dose). No increases in tumour incidence attributable to
vildagliptin were observed. Another two-year carcinogenicity study was conducted in mice at oral doses up to
1,000 mg/kg. An increased incidence of mammary adenocarcinomas and haemangiosarcomas was observed
with a no-effect dose of 500 mg/kg (59-fold human exposure) and 100 mg/kg (16-fold human exposure),
respectively. The increased incidence of these tumours in mice is considered not to represent a significant risk
to humans based on the lack of genotoxicity of vildagliptin and its principal metabolite, the occurrence of
tumours only in one species and the high systemic exposure ratios at which tumours were observed.
In a 13-week toxicology study in cynomolgus monkeys, skin lesions have been recorded at doses ≥ 5
mg/kg/day. These were consistently located on the extremities (hands, feet, ears and tail). At 5 mg/kg/day
(approximately equivalent to human AUC exposure at the 100 mg dose), only blisters were observed. They
were reversible despite continued treatment and were not associated with histopathological abnormalities.
Flaking skin, peeling skin, scabs and tail sores with correlating histopathological changes were noted at doses
≥ 20 mg/kg/day (approximately 3 times human AUC exposure at the 100 mg dose). Necrotic lesions of the tail
were observed at ≥ 80 mg/kg/day. Skin lesions were not reversible in the monkeys treated at 160 mg/kg/day
during a 4-week recovery period.

Microcrystalline Cellulose, Lactose anhydrous, Sodium Starch Glycolate, and Magnesium Stearate.

Not applicable.

Store below 30°C.
Store in the original package in order to protect from moisture.

Packages: 4 blisters (14 tablets / blister) are attached to a leaflet and inserted in an internal carton box.
available in packs containing 56 tablets.

No special requirements.